{"DataElement":{"publicId":"2730467","version":"1","preferredName":"Other Concomitant Breast Carcinoma Medication Received Text","preferredDefinition":"Text description of concomitant therapy agents received for breast cancer different than the one(s) previously specified or mentioned. [Manually-curated]","longName":"OTX_CONCOM_RECD_TXT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2730465","version":"1","preferredName":"Other Concomitant Breast Carcinoma Medication Received","preferredDefinition":"information relating to concomitant medication received in a breast cancer treatment trial._Different than the one(s) previously specified or mentioned. (NCI)_Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"OTX_CONCOM_BRST_MED","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2730463","version":"1","preferredName":"Other Concomitant Breast Carcinoma Medication","preferredDefinition":"Not otherwise specified.:Concomitant; following as a consequence.:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C17649:C25730:C4872:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A4507-8543-55AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"ONEDATA","dateModified":"2008-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"469A4507-8551-55AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2720665","version":"1","preferredName":"Other Treatment Text","preferredDefinition":"The text used to describe the action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process that is different than the one(s) previously specified or mentioned.","longName":"OTHER_TX_TXT","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008573","version":"1","preferredName":"Adverse Event Results","preferredDefinition":"the outcome or resolution of the patient's adverse events.","longName":"AE_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB869948-5E78-2537-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2720664","version":"1","preferredName":"Other Therapeutic Procedure Text","preferredDefinition":"Not otherwise specified.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Text; the words of something written.","longName":"C17649:C49236:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43C691AF-CA66-21CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2008-01-15","modifiedBy":"ONEDATA","dateModified":"2008-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43C691AF-CA77-21CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2008-01-15","modifiedBy":"CURTIST","dateModified":"2010-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812734","version":"1","longName":"U Washington New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other (specify)","type":"Preferred Question Text","description":"Other (specify)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"469B100C-18A5-0684-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated to support U Washington adoption of C3D for FES trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}